Posts By Alex
-
369Wire StoriesTakeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared...
-
400Wire StoriesVista Gold Corp. Presenting at the 2023 Precious Metals Summit
DENVER–(BUSINESS WIRE)–Vista Gold Corp. (NYSE American and TSX: VGZ) (“Vista” or the “Company”) announced today that management will hold one-on-one investor meetings...
-
382Wire StoriesNetcracker Launches Pioneering Solution to Advance Generative AI for the Telecom Industry
Netcracker GenAI Telco Solution Accelerates the Adoption of High-Value Use Cases Across the Telecom Business WALTHAM, Mass.–(BUSINESS WIRE)–Netcracker Technology announced today its...
-
389Wire StoriesHeartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
TOKYO–(BUSINESS WIRE)–#HS001–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two...
-
338Wire StoriesSINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Clinical trials will advance treatment of COVID-19 infection. BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of...
-
390Wire StoriesAustralianSuper Backs Vantage Data Centers with €1.5 Billion Investment and Joins DigitalBridge as Key Shareholder
MELBOURNE, Australia & BOCA RATON, Fla. & DENVER–(BUSINESS WIRE)–AustralianSuper, Australia’s largest pension fund, today announced that it is investing €1.5 billion to...
-
414Wire StoriesENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in...
-
353Wire StoriesGlobal Chemicals Market 2023 to 2027, Fueled by Growing Demand Across Industries – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Chemicals Market (by Category & Region): Insights & Forecast with Potential Impact of COVID-19)” report has been added to...
-
493Wire StoriesElliptic Labs Signs PoC Contract with PC OEM, Bringing NEW Seamless and Cohesive User Experience Across the Product Lineup
OSLO, Norway–(BUSINESS WIRE)–#AI—Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed...
-
389Wire StoriesLRN Appoints New Leadership for Asia-Pacific Region
Dean Rogers to Oversee Growth After Integration of Recent Compliance Learning Acquisition from Thomson Reuters TOKYO–(BUSINESS WIRE)–LRN Corporation, the leader in ethics...
